Journal article
Gustavo Romero‐Velez, Ludovico Sehnem, S. Noureldine, Gilman Plitt, Bletsis Panagiotis, Joyce J. Shin, A. Siperstein
Endocrine Practice, 2024
Endocrine Practice, 2024
Semantic Scholar
DOI
PubMed
Cite
Cite
APA
Click to copy
Romero‐Velez, G., Sehnem, L., Noureldine, S., Plitt, G., Panagiotis, B., Shin, J. J., & Siperstein, A. (2024). Progression of nodular thyroid disease in Familial Adenomatous Polyposis syndrome: refined surveillance recommendations. Endocrine Practice.
Chicago/Turabian
Click to copy
Romero‐Velez, Gustavo, Ludovico Sehnem, S. Noureldine, Gilman Plitt, Bletsis Panagiotis, Joyce J. Shin, and A. Siperstein. “Progression of Nodular Thyroid Disease in Familial Adenomatous Polyposis Syndrome: Refined Surveillance Recommendations.” Endocrine Practice (2024).
MLA
Click to copy
Romero‐Velez, Gustavo, et al. “Progression of Nodular Thyroid Disease in Familial Adenomatous Polyposis Syndrome: Refined Surveillance Recommendations.” Endocrine Practice, 2024.
BibTeX Click to copy
@article{gustavo2024a,
title = {Progression of nodular thyroid disease in Familial Adenomatous Polyposis syndrome: refined surveillance recommendations.},
year = {2024},
journal = {Endocrine Practice},
author = {Romero‐Velez, Gustavo and Sehnem, Ludovico and Noureldine, S. and Plitt, Gilman and Panagiotis, Bletsis and Shin, Joyce J. and Siperstein, A.}
}
Abstract
BACKGROUND Patients with familial adenomatous polyposis (FAP) have an increased risk of thyroid nodular disease. Previous studies demonstrated that screening thyroid ultrasound (US) will allow detection of nodules in 38% and thyroid cancer in 2.6% of patients. The aim of this study is to define the value of serial US evaluation at identifying disease progression in patients with FAP.
METHODS Retrospective review from 2008-2023 at a single referral center. All patients with FAP and screening thyroid US were included. Patient demographics, initial US characteristics, follow-up regarding the development of new nodules and cancer were assessed using a Kaplan-Meier analysis.
RESULTS A total of 556 patients underwent screening. 51% were male. Median age at first screening was 38 years old. 81% underwent longitudinal follow-up for a median length of 7 years. At initial screening, 169 patients (30%) had nodules. For patients with normal baseline US, 14% developed a nodule overtime. A total of 20 patients (3.6%) were diagnosed with thyroid cancer. The cumulative incidence of initial and subsequent cancer was 4% by 5-years and 6% by 10-years, while the cumulative incidence of thyroid nodules was 40% and 48%, respectively.
CONCLUSIONS Based on the Kaplan-Meier analysis, ongoing longitudinal screening is warranted for patients with FAP as they are prone to thyroid cancer and nodule development overtime even when presenting with a baseline normal US. Additionally, these data demonstrate a slow development of thyroid cancer from a normal US, thus it is reasonable to consider selectively extending the screening interval for this population.